Epinephrine is a potent neurotransmitter and hormone that can influence cardiac performance beginning shortly after the first myocardial contractions occur in developing vertebrate embryos. In the present study, we provide evidence that the heart itself may produce epinephrine during embryonic development. Using antibodies that selectively recognize the catecholamine biosynthetic enzymes, tyrosine hydroxylase, dopamine ␤-hydroxylase, and phenylethanolamine N-methyltransferase, we used coimmunofluorescent staining techniques to identify cardiac cells that have the capability of producing catecholamines. Initially, cells expressing catecholamine biosynthetic enzymes were found interspersed throughout the myocardium, but by embryonic day 11.5 (E11.5), they became preferentially localized to the dorsal venous valve and atrioventricular canal regions. As development proceeded, catecholamine biosynthetic enzyme expression decreased in these regions but became quite strong along the crest of the interventricular septum by E16.5. This expression pattern was also transient, decreasing in the ventricular septum by E19.5. These data are consistent with a transient and progressive association of catecholamine-producing cells within regions of the heart that become the sinoatrial node, atrioventricular node, and bundle of His. This is the first evidence demonstrating that intrinsic cardiac adrenergic cells may be preferentially associated with early pacemaking and conduction tissue development. (Circ Res.  2001;88:117-124.) 
E pinephrine and norepinephrine, the primary peripheral catecholamines in most vertebrates, are neurotransmitters and hormones that have profound influences on cardiac function beginning almost as soon as the heart starts to beat and continuing through all remaining stages of development. In adult mammals, peripheral catecholamines are primarily produced in the adrenal medullae and sympathetic ganglia by the enzymatic conversion of L-tyrosine, as illustrated in Figure 1 .
Recent evidence suggests that the mammalian heart may be a source of catecholamines at early developmental stages. 1, 2 Catecholamine biosynthetic enzymes have been detected in the embryonic heart long before either sympathetic innervation of the heart or production of catecholamines in adrenal chromaffin cells. 1, 2 In rats, for example, the epinephrine biosynthetic enzyme phenylethanolamine N-methyltransferase (PNMT) is expressed in the heart as early as embryonic day 9.5 (E9.5), whereas the earliest appearance of this enzyme in the adrenal gland does not occur until E15.5 to E16.5. 1, 3 Similarly, sympathetic nerves do not appear in the developing rat heart until E16 to E17. 4 Parasympathetic innervation of the heart occurs much earlier than sympathetic innervation 5 but does not begin to appear until E12 in the rat. 6 By this stage of development (E12), the relative abundance of cardiac PNMT mRNA is already starting to decrease, having reached peak levels between E10 and E11. 1 Studies with chick and human embryos have likewise demonstrated the expression of catecholamine biosynthetic enzymes in the heart before sympathetic innervation. 2, 7, 8 Thus, the embryonic heart seems to have the capability of producing catecholamines at stages of development that precede production of catecholamines in the adrenal gland and cardiac sympathetic nerves.
Although chromaffin-like and small intensely fluorescent catecholaminergic cells have been found in and around adult hearts from many species, 9 -13 typically in association with cardiac nerves, few studies have examined catecholamine production in the prenatal heart. Consequently, the goal of the present study was to identify and map the location of cells expressing the major catecholamine biosynthetic enzymes (PNMT, dopamine ␤-hydroxylase [DBH] , and tyrosine hydroxylase [TH]) in the developing embryonic rat heart.
Materials and Methods

Animals
All animal studies conformed with the guidelines prescribed by the Georgetown University Animal Care and Use Committee and the National Institutes of Health. Timed pregnant Sprague-Dawley rats were obtained from Taconic Labs (Germantown, NY). Embryos were isolated, staged, and dissected as described previously. 1
Immunofluorescence Histochemistry
Double-and single-immunofluorescent staining of developing rat hearts was performed essentially as described previously. 14 Anti-PNMT and anti-DBH antisera are polyclonal rabbit antisera raised against PNMT and DBH purified from bovine adrenal chromaffin cells 15, 16 and were kindly provided by Dr D.L. Wong (Harvard University Medical School, Boston, Mass). The anti-TH and anti-␣-actinin antisera are mouse monoclonal antibodies (ascites) obtained from Sigma Chemical Co. Secondary antibodies (FITCconjugated donkey anti-rabbit IgG, TRITC-conjugated donkey antimouse IgG, Texas Red-conjugated donkey anti-rabbit IgG, and Texas Red-conjugated donkey anti-mouse IgG) were obtained from Jackson Labs and used at a dilution of 1:200.
Epinephrine Radioimmunoassay
Embryonic samples were prepared by sonication for 10 seconds in 0.1 mol/L HCl, followed by microcentrifugation (14 000g, 10 minutes) to remove residual debris. Protein concentrations were determined for the supernatants using the Bio-Rad protein assay, and equivalent amounts of each sample (1 g protein diluted in 1 mL of 0.1 mol/L HCl) were assayed using a commercially available radioimmunoassay (ALPCO Labs, Inc).
An expanded Materials and Methods section can be found in an online data supplement available at http://www.circresaha.org.
Results
Transient expression of the gene encoding the epinephrine biosynthetic enzyme, PNMT, has previously been demonstrated in the preinnervation-stage embryonic rat heart using enzymatic and RNase protection assays. 1 To identify the cells that express PNMT within the heart, we initiated immunofluorescent histochemical staining using a rabbit anti-PNMT antiserum 15 and an FITC-conjugated anti-rabbit IgG secondary antibody. At relatively early stages of development (eg, E10.5), PNMT expression was detected throughout the developing myocardium (Figure 2A ). Specifically, PNMT expression was observed in the truncus arteriosus as well as the common atrial and ventricular chambers at this stage of development (E10.5, Figures 2A through 2F ). In contrast, no staining for PNMT was seen in nearby aortic arch tissue (Figures 2A through 2C and 2F, small arrows). To visualize cardiac cells expressing PNMT relative to those expressing muscle-specific proteins, we performed coimmunofluorescent staining with antibodies that selectively recognize either PNMT or the muscle-specific protein sarcomeric ␣-actinin. 18 As shown in Figures 2A and 2B , a similar but partially nonoverlapping pattern of expression was found in the E10.5 rat heart for these 2 proteins. This can be observed with greater clarity in the higher magnification photomicrographs shown in Figures 2D and 2E . To facilitate comparison, the arrow depicted in Figures 2A through 2F points to the same region of the truncus arteriosus. Although it appears that some overlapping expression of PNMT and ␣-actinin occurs (compare Figures 2A and 2B ), there are distinct regions of nonoverlapping expression (compare Figures 2D and 2E ). In particular, whenever we observed bright, intense staining for ␣-actinin, we did not see coexpression of PNMT in those cells, although adjacent or nearby cells often were intensely stained for PNMT. Many blood cells found in the atrial chamber shown in Figures 2A through 2C were also fluorescently labeled when viewed with either filter set, but this staining was not specific, because it could also be observed in the absence of both primary antibodies (data not shown). For orientation, the embryo sections were stained with hematoxylin and eosin (H&E) after the fluorescent staining procedure, and photomicrographs of these H&E sections are shown in the rightmost column of Figure 2 .
Two days later in development (E12.5), PNMT immunostaining remained strong at the atrioventricular (AV) junction (Figures 2G through 2L, arrow) but was decreased considerably in the truncus arteriosus and most other regions of the heart, although limited expression was seen interspersed throughout the myocardium. Endocardial-cushion tissue development was prominent at E12.5 ( Figures 2I and 2L ), but neither ␣-actinin nor PNMT expression was detected in the cushions. The remaining panels of Figure 2 depict control immunofluorescent staining. For example, Figures 2M through 2O illustrate cardiac muscle fibers from a postnatal day 8 (P8) rat ventricle. No PNMT expression was observed in this region at this stage of development ( Figure 2M ), but ␣-actinin staining was strong and produced a characteristic Z-banding pattern ( Figure 2N ), as expected for a sarcomeric protein. Conversely, PNMT expression was robust and localized to the medulla of a P8 adrenal gland section ( Figure 2P ), whereas ␣-actinin staining was completely absent from the adrenal section ( Figure 2Q ). These results demonstrate the specificity of the PNMT and ␣-actinin antibodies and show that there is no cross-reactivity or bleed-through staining of the immunofluorescent signals.
Endogenous production of epinephrine typically requires the coexpression of DBH and TH in the same cells that express PNMT (see Figure 1 ). Therefore, we extended our immunofluorescent histochemical staining analysis of the developing embryonic rat heart to include antibodies that specifically recognize DBH and TH. Because the anti-DBH antiserum was produced in rabbits while the anti-TH ascites fluid was produced in mice, we were able to perform double-immunofluorescent labeling experiments with these antibodies. In our initial experiments with these antibodies, we optimized antibody concentrations and verified the specificity of immunofluorescent labeling using adult rat adrenal gland sections (see the online data supplement available at http://www.circresaha.org). To provide anatomical orientation, we initially captured low-magnification images of a mid-sagittal E11.5 rat heart section coimmunofluorescently labeled for PNMT and ␣-actinin ( Figures 3A and 3B , respectively). In this section, PNMT immunofluorescent labeling was largely concentrated in the caudal-dorsal portion of the atrium (arrow), immediately adjacent to the venous inlet. Other regions of this section show limited staining for PNMT, although we typically observed some staining in the region immediately caudal to the heart and rostral to the hepatic primordium. The PNMT-stained cells in this region showed no costaining for ␣-actinin and were located outside of the cardiac chamber walls. Nevertheless, cells in this region are thought to subsequently give rise to the epicardium. 19 Within the heart, the cluster of fluorescent cells in the atrial wall immediately adjacent to the dorsal venous valve represents a predominant site of PNMT expression at this stage of development. Note that ␣-actinin staining intensity in this region appears to be inversely proportional to the PNMT staining in the same section ( Figures 3A and 3B ). Highermagnification images of this cell cluster are shown in Figures  3C and 3D (arrow). At this increased magnification, it is clear that some individual cells are stained for both markers, whereas others stain for either PNMT or ␣-actinin but not both. DBH and TH immunostaining in an adjacent section from this same E11.5 rat heart produced a pattern of staining that was very similar to that shown for PNMT (Figures 3E through 3H). A high concordance of immunostaining was observed for DBH and TH ( Figures 3E and 3F , respectively) as well as for PNMT and TH ( Figures 3G and 3H , respectively) in these sections, indicating that expression of catecholamine biosynthetic enzymes was specifically concentrated in a clustering of cells located in the dorsal-caudal region of the primitive atrial wall immediately adjacent to the venous valve at E11.5. Because the sinoatrial (SA) node has also been described in this region at similar stages of development in the mouse, 20 our data suggest an association between catecholamine biosynthetic enzyme expression and development of the SA node in the E11.5 rat heart.
In other sections from E11.5 rat embryos, we have observed clusters of cells expressing catecholamine biosynthetic enzymes in the AV canal region. For example, the confocal images depicted in Figure 4 show DBH (green) and ␣-actinin (red) expression in another mid-sagittal section of an E11.5 rat heart. The yellow regions represent areas where DBH and ␣-actinin are colocalized ( Figure 4A , arrows). As shown in Figure 3 , there is a concentration of DBH staining in the dorsal venous-valve region of the atrium and sporadic staining in the walls of the atrium, ventricle, and outflow tract ( Figure 4A ). In addition, prominent DBH staining was observed in the AV canal region (Figure 4 , bracketed region). This staining is particularly evident in the highermagnification image shown in Figure 4B . To gain a more 3-dimensional perspective, we used the confocal microscope to capture optical sections (2 m/section) through the AV canal region. We then reconstructed these images by stacking the inner ( Figure 4C ) and outer ( Figure 4D ) optical layers. The cardiac muscle fibers in this region have well-developed Z-bands, and they appear to form a lattice network, with isolated clusters of small roundish DBH-expressing cells found within this lattice. There seems to be very little overlapping expression for DBH and ␣-actinin in the same cells within the AV canal region. Similar patterns of staining were observed for TH and PNMT in other sections (Figure 3 and unpublished data, February 1998). Thus, these data show that there are two regions within the E11.5 rat heart where catecholamine biosynthetic enzyme expression is concentrated: AV canal and atrial wall adjacent to the dorsal venous valve cusp.
We also examined cells that express catecholamine biosynthetic enzymes at later stages of embryonic development and found a dramatic shift in their distribution within the heart. Notably, at E16.5 we observed a major concentration of putative epinephrine-producing cells along the crest of the interventricular septum ( Figures 5 and 6) . For example, a concentrated cluster of cells displaying intense immunofluorescent staining for PNMT expression was observed in the anterior portion of the interventricular septum, with isolated sporadic cell staining occurring in the middle and lower regions of the ventricular septum ( Figure 5A ). To provide a reference for cardiac muscle cells in this region, ␣-actinin immunostaining was simultaneously performed. Intense ␣-actinin immunofluorescent staining was observed in muscle throughout this region ( Figure 5B ). As we observed at earlier developmental stages, ␣-actinin staining intensity was Note that some cells are clearly costained for PNMT and ␣-actinin when visualized at higher magnification (compare panels C and D, ϫ40 objective), whereas other cells express only one or the other of these markers. Sagittal sections adjacent to the one shown in A through D were double-stained for DBH and TH (E and F, respectively) or PNMT and TH (G and H, respectively). DBH and PNMT were visualized with the FITC filter, whereas TH was observed using the TRITC filter. Note the nearly identical patterns of staining for these enzymes in these atrial tissue sections. OT indicates outflow tract; At, atrium; and V, ventricle. inversely proportional to PNMT staining intensity in these sections (compare Figures 5A and 5B ). DBH and TH staining patterns were very similar to those observed for PNMT at this stage of development, and these enzymes appear to be colocalized in a knot of cells within the upper portion of the ventricular septum ( Figures 5C and 5D ). This pattern of expression resembles the developing bundle of His and, to a lesser extent, ventricular conduction tissue (ie, Purkinje fibers) that has been described at analogous stages of development in mouse embryos. 21 To examine this expression in greater detail, we used laser-scanning confocal fluorescence microscopy after DBH immunofluorescent labeling of transverse sections through this region of the heart. Again, we observed a concentrated cluster of positively labeled cells at the crest of the interventricular septum ( Figure 6 ). Note that the images shown in Figures 6A and 6B are Ϸ100 m anterior to the sections shown in Figures 6C and 6D . The DBH-expressing cells were clearly more concentrated in the anterior portion of the ventricular septum, as was observed in Figure 6 . At higher magnification ( Figures 6B and 6D) , individual cell staining could be discriminated. The pattern of staining at the singlecell level appeared to be predominantly cytoplasmic, although the distribution within the cytoplasm was splotchy and nonuniform. Although not shown in these images, relatively little staining for catecholamine biosynthetic enzymes was observed in the SA-and AV-node regions at E16.5 and later stages of development, although a few positively labeled cells were observed in these regions. In addition, at somewhat later stages of development (eg, E19.5), we did not observe this intense cell labeling along the crest of the interventricular septum after immunofluorescent staining for catecholamine biosynthetic enzyme expression (data not shown). These data suggest a transient association between cardiac catecholamine-producing cells and pacemaking and conduction tissue development. A summary of these results is provided in the Table. At each of the developmental stages indicated, we observed approximately 200 to 500 cardiac cells that were immunofluorescently stained for catecholamine biosynthetic enzymes.
The coexpression of the major catecholamine biosynthetic enzymes in embryonic cardiac cells before innervation suggests that epinephrine is produced in the embryonic rat heart. To determine the epinephrine content of the embryonic rat heart, we isolated hearts from head and trunk regions of E11.5 rat embryos, as described previously, 1 and used this material for epinephrine radioimmunoassays. The combined results of 5 separate experiments are shown in Figure 7A , where low but detectable concentrations of epinephrine were found in the heart, head, and trunk regions of E11.5 rat embryos. On average, there was Ϸ30% more epinephrine found in the heart than in either the head or the trunk of E11.5 rat embryos, but these differences were not significant (PϾ0.05). However, the amount of epinephrine detected in each of these regions was significantly greater 
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than background (PϽ0.001). We estimated the amount of epinephrine in the E11.5 rat heart on a per-cell basis and compared it with the amount of epinephrine found on a per-cell basis in an adult rat adrenal chromaffin cell. A conservative estimate, on the basis of data generated in the present study, is 3.5ϫ10 Ϫ8 mol epinephrine per adult rat adrenal chromaffin cell. This estimate is similar to the amount of epinephrine reported per adult rat adrenal chromaffin cell (1.4ϫ10 Ϫ7 mol) by Tomlinson et al 22 and translates to Ϸ5ϫ10 10 molecules epinephrine per adult adrenal chromaffin cell. By comparison, we calculated that, on average, there were at least 1.6ϫ10 6 molecules (2.7ϫ10 Ϫ12 mol) epinephrine per E11.5 rat catecholaminergic cardiac cell. Although the amount of epinephrine present in the embryonic rat heart was substantially less than that found in a typical adrenal gland (Ϸ50 000-fold fewer molecules of epinephrine on a per-cell basis), our results nevertheless demonstrate that epinephrine and the enzymatic machinery necessary for its synthesis are present in the preinnervationstage embryonic rat heart.
To assess epinephrine concentrations in the developing rat embryo at different developmental stages, we measured the amount of epinephrine present relative to the total amount of protein present in extracts from heart, head, and trunk regions from pooled tissue samples isolated at various stages of embryonic development. As shown in Figure 7B , cardiac epinephrine concentrations were relatively low at early stages of development but slowly began to increase at ϷE13.5 and continued through at least E19.5. These results show that epinephrine was present in the embryonic rat heart beginning at very early stages of cardiac development and, in contrast to cardiac PNMT mRNA expression, gradually increased at later stages of prenatal development.
Discussion
The conduction system of the mammalian heart consists of the SA node, AV node, bundle of His, and ventricular Purkinje fibers. 23 Our results show that cardiac cells expressing catecholamine biosynthetic enzymes are present in the embryonic heart, where they seem to be progressively associated with each of these regions of the cardiac conduction system. Beginning ϷE11.5 in the rat, catecholamine biosynthetic enzymes were expressed in cardiac cells preferentially localized to the atrial wall adjacent to the dorsal venous valve cusp and the AV canal. Cells within these regions of the heart develop into the SA and AV nodes, respectively. 20, 21, 24 Thus, catecholamine-producing cells were concentrated in regions of the embryonic heart that later become the SA and AV nodes. A similar phenomenon was observed several days later in embryonic development (E16.5), when cells expressing catecholamine biosynthetic enzymes were found clustered in the developing bundle of His and, to a lesser extent, in the ventricular septum where the branching bundles and Purkinje fibers of the ventricular conduction system would be expected to appear.
The association between catecholamine-producing cells and the development of the cardiac conduction system was essentially transient, because early expression (before E11.5) did not seem to be specifically localized to any particular region of the developing heart. Moreover, the clusters of adrenergic cells in regions of the heart that give rise to the SA and AV nodes were not found in these regions after ϷE12.5, and the labeled cells found concentrated in the bundle of His region at E16.5 were no longer concentrated in this region by E19.5. These data suggest two windows of development when adrenergic cells are preferentially associated with pacemaking and conduction tissue. The first window occurs between E10.5 and E13.5 and primarily involves atrial components (future SA and AV nodes), whereas the second, occurring between E13.5 and E19.5, involves ventricular components (bundle of His and ventricular septum) of the cardiac conduction system. It is perhaps because of this limited and transient pattern of expression that these cells were overlooked in previous studies. Consequently, this is the first report that identifies a population of putative catecholamine-producing cells that are progressively and transiently associated with embryonic cardiac conduction tissue development. Interestingly, such increasingly restricted localization to early conduction tissue of reactivity initially dispersed throughout the tubular heart has been observed with several other markers, including atrial natriuretic peptide, 25, 26 leu-7, 27,28 and embryonic avian polypeptide. 29 The specific origin of cardiac catecholamine-producing cells is not known, but they do not seem to be neuronal, because they do not have a neuronal morphology and they are present in the heart several days before the first appearance of nerve-like cells in and around the heart. 6 In addition, unlike the catecholamine-producing cells of the adrenal medulla, the cardiac cells that express catecholamine biosynthetic enzymes do not seem to be derived from the neural crest. Fate-mapping and ablation studies have shown that cardiac neural crest cells migrate into the heart and contribute to outflow septation, formation of cardiac ganglia, and development of aortic arteries. 30 Because the pattern of expression observed for catecholamine biosynthetic enzymes in the developing rat heart was completely different from the reported distribution of neural crest cells within the embryonic heart, it seems unlikely that the adrenergic cells identified in the present study were of neural crest origin.
Instead, these adrenergic cells seem to be intrinsically derived from the primitive myocardium. In support of this hypothesis, we demonstrated that some embryonic cardiac cells coexpressed catecholamine biosynthetic enzymes and the muscle-specific marker ␣-actinin. However, most of the cells that we observed expressed either ␣-actinin or catecholamine biosynthetic enzymes. These data suggest that cardiac cells expressing these 2 biomarkers could be derived from common progenitor cells in the developing cardiac primordium and are consistent with the findings of Huang et al, 2 who recently described a population of intrinsic cardiac adrenergic cells in rat and human hearts.
We have shown that low concentrations of epinephrine are present in the embryonic rat heart at least as early as E11.5. We also detected epinephrine in the head and trunk regions in E11.5 rat embryos. However, because the heart is the primary endogenous tissue source for the major epinephrineproducing enzymes (TH, DBH, and PNMT) at this stage of embryonic rat development, we hypothesize that most of the epinephrine detected in E11.5 rat embryos was synthesized in the heart. It could have been secreted from embryonic catecholamine-producing cells in the heart, although it is not clear whether this would have occurred in vivo or during the isolation and dissection procedures. In addition, contributions from maternal sources and other embryonic tissues, such as developing lung buds (see Figure 2 online, available at http://www.circresaha.org), cannot be ruled out. Interestingly, epinephrine concentrations actually increase in the heart at later stages of prenatal development despite declining PNMT mRNA concentrations in the heart after E12.5. 1 At these later stages of prenatal development (E13.5 through E19.5), the appearance of adrenergic nerves in the central and peripheral nervous systems 5 may contribute to some of the increases in epinephrine content observed in the heart as development proceeds. Similarly, adrenal chromaffin cells begin to produce epinephrine beginning ϷE15.5 to E16.5 and likely contribute to the rise in peripheral epinephrine concentrations observed at this and later stages of development. 3 Studies dating back to the 1930s have demonstrated that explanted embryonic chick hearts are responsive (increased heart rate) to exogenously administered epinephrine soon after the heart begins to beat. 31, 32 However, it is clear that very early stage intrinsically beating hearts (eg, E2) do not generally respond to epinephrine until Ϸ1 day later (ie, E3). 31, 32 In the developing rat embryo, increased heart rate after isoproterenol treatment has been demonstrated as early as E10.5. 33, 34 Similar to the chick studies, full responsiveness and coupling of ␤-adrenergic receptors to second messengers and ion channel activities seem to mature at least 1 or 2 days after the initiation of spontaneous myocardial contractions and the appearance of ␤-adrenergic receptor expression in developing cardiac cells. 35 Consequently, because the heart is responsive to the actions of catecholamines at relatively early developmental stages, 33 local production of catecholamines in the heart could play a significant role in regulating the beating activity or differentiation of embryonic myocardial cells. This hypothesis is supported by the finding that intrinsic heart rates of transgenic mouse embryos lacking the ability to produce catecholamines were significantly slower than their age-matched wild-type counterparts and typically died in utero from cardiovascular failure. 36 -38 The vast majority of these deaths occurred between E11.5 and E15.5, which roughly corresponds to the developmental period between E13 and E17 in the rat. Because we observed expression of intrinsic cardiac catecholamine biosynthetic enzyme expression in the heart during this period as well as during the period immediately preceding this window of development, intrinsic production of catecholamines locally within the heart could play an important role in the development of cardiac function. One might expect that the conduction system in these mouse hearts may not have developed properly and that this could have contributed to the bradycardia and eventual cardiovascular failure. Additional functional studies are necessary to test this and other hypotheses regarding the role of intrinsic catecholamine production in the developing embryonic heart.
